EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
Patient with anti-PL-12 syndrome and lymphoma: a rare case report
This review of a case report describes a patient with anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma.
A single patient with anti-PL-12 antisynthetase syndrome and NK/T-cell lymphoma highlights the need for caution when interpreting rare cance…
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
New Strategies to Keep CAR-T Cells Strong Against Cancer
This narrative review examines strategies to prevent CAR-T cell exhaustion in patients with treatment-resistant non-Hodgkin lymphoma.
This review explains how to stop immune cells from giving up on fighting cancer.
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
Systematic review finds highest glyphosate exposure associated with increased NHL risk
Higher glyphosate herbicide exposure linked to increased lymphoma risk in research review
A systematic review and meta-analysis of 20 observational study populations found that ever exposure to glyphosate-based herbicides was not …
People with the highest glyphosate herbicide exposure had about a 38% higher chance of developing non-Hodgkin's lymphoma compared to those w…
Research across Cancer
Related studies from across the Cancer family.
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Case report and literature review highlights skin lesions as early AITL signs before lymphadenopathy
When a Skin Rash Signals a Hidden Blood Cancer
This case report and literature review examines cutaneous manifestations in a 63-year-old male with Angioimmunoblastic T-cell lymphoma treat…
A rare lymphoma can hide behind common-looking skin rashes and ulcers, causing dangerous delays in diagnosis that may last months.
Literature review on primary CNS MALT lymphoma treatment and diagnosis
A Rare Brain Tumor in the Ventricles Was Found and Treated
This literature review and case report describes a 62-year-old man with primary central nervous system mucosa-associated lymphoid tissue lym…
A 62-year-old man had a rare brain tumor inside a fluid-filled ventricle, and a new treatment plan kept it from coming back.
Narrative review of treatment strategies for primary central nervous system lymphoma
A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
Systematic review and meta-analysis of interim FDG PET in large B-cell lymphoma patients
Early PET scans help doctors predict how well large B-cell lymphoma treatments will work for patients
This systematic review and meta-analysis evaluated the utility of interim FDG PET (iPET) in 44 eligible studies involving large B-cell lymph…
A review of many studies shows that early PET scans can tell doctors if cancer treatment is working. This helps them decide the best next st…
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
1. HEADLINE
This case report and literature review describes a 66-year-old male with stage IV HIV-associated diffuse large B-cell lymphoma.
HIV Treatment Clears Advanced Lymphoma Without Chemo
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Questions about Lymphoma
Which EBUS technique works best for diagnosing lymphoma in the mediastinum?
EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) has the highest diagnostic yield for lymphoma in the mediastinum, outperforming standard EBUS-TBNA.
Full answer →